Brodalumab (Siliq™)


FDA approved Indication:

Treatmnet of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Patients must meet the following criteria for Plaque Psoriasis:

  • Diagnosis of moderate to severe plaque psoriasis confirmed by a dermatologist, AND
  • Baseline PASI score of 10 or more, AND
  • One of the following:
    • Inadequate response, intolerance or contraindication to PUVA or UVB treatment, OR,
    • Has difficulty accessing PUVA or UVB. AND
  • One of the following:
    • Experienced inadequate response/intolerance to at least one of the following treatments: methotrexate, cyclosporine (Neoral), acitretin (Soriatane), OR
    • Contraindication to all the treatments listed.  (A trial of these agents is not applicable for females actively attempting to conceive). AND
  • Inadequate response or intolerable side effects to two of the following: Humira, Stelara, Cosentyx, Otezla, or Tremfya, AND
  • Siliq will not be used concomitantly with other biologic DMARDs, AND
  • Patient does not have Crohn's disease


  • 210 mg administered by subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks

Approval Period:

  • Initial approval 3 months to assess patient's response
  • Renewal for one year if patient has clinical response

Risk of Tuberculosis:

Patients should be evaluated for latent tuberculosis infection with a TB skin test.  Treatment of latent tuberculosis infection should be initiated prior to therapy with Siliq.

Last review date: May 1, 2019